{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:51:51Z","timestamp":1785595911863,"version":"3.56.0"},"reference-count":28,"publisher":"Pharmaceutical Society of Japan","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1248\/bpb.b20-00553","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T22:11:45Z","timestamp":1606774305000},"page":"1969-1974","source":"Crossref","is-referenced-by-count":11,"title":["Pharmaceutical Care Contributes to the Advanced Management of Patients Receiving Immune Checkpoint Inhibitors"],"prefix":"10.1248","volume":"43","author":[{"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Cancer Center, Hokkaido University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"},{"name":"Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Saito Y, Harada S, Kobayashi M, Ueda K, Yamazaki K, Kumai M, Miyamoto T, Kasashi K, Yamada T, Komatsu Y, Iseki K. Survey of the efficacy of long-term and successive pharmaceutical care in outpatient chemotherapy by oncology pharmacy specialists. Yakugaku Zasshi<\/i>, 138<\/b>, 1409\u20131416 (2018).","DOI":"10.1248\/yakushi.18-00081"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Iihara H, Ishihara M, Matsuura K, Kurahashi S, Takahashi T, Kawaguchi Y, Yoshida K, Itoh Y. Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic. J. Eval. Clin. Pract.<\/i>, 18<\/b>, 753\u2013760 (2012).","DOI":"10.1111\/j.1365-2753.2011.01665.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Muluneh B, Schneider M, Faso A, Amerine L, Daniels R, Crisp B, Valgus J, Savage S. Improved adherence rates and clinical outcomes of an integrated, closed-loop, pharmacist-led oral chemotherapy management program. J. Oncol. Pract.<\/i>, 14<\/b>, e324\u2013e334 (2018).","DOI":"10.1200\/JOP.17.00039"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Segal EM, Bates J, Fleszar SL, Holle LM, Kennerly-Shah J, Rockey M, Jeffers KD. Demonstrating the value of the oncology pharmacist within the healthcare team. J. Oncol. Pharm. Pract.<\/i>, 25<\/b>, 1945\u20131967 (2019).","DOI":"10.1177\/1078155219859424"},{"key":"5","unstructured":"5) Colombo LRP, Aguiar PM, Lima TM, Storpirtis S. The effects of pharmacist interventions on adult outpatients with cancer: a systematic review. J. Clin. Pharm. Ther.<\/i>, 42<\/b>, 414\u2013424 (2017)."},{"key":"6","unstructured":"6) Dine J, Gordon R, Shames Y, Kasler MK, Barton-Burke M. Immune checkpoint inhibitors: an innovation in Immunotherapy for the treatment and management of patients with cancer. Asia Pac. J. Oncol. Nurs.<\/i>, 4<\/b>, 127\u2013135 (2017)."},{"key":"7","unstructured":"7) Fessas P, Possamai LA, Clark J, Daniels E, Gudd C, Mullish BH, Alexander JL, Pinato DJ. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology<\/i>, 159<\/b>, 167\u2013177 (2020)."},{"key":"8","unstructured":"8) Brahmer JR, Lacchetti C, Schneider BJ, et al.<\/i> Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol.<\/i>, 36<\/b>, 1714\u20131768 (2018)."},{"key":"9","unstructured":"9) Hodi FS, O\u2019Day SJ, McDermott DF, et al.<\/i> Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.<\/i>, 363<\/b>, 711\u2013723 (2010)."},{"key":"10","unstructured":"10) Kwon ED, Drake CG, Scher HI, et al.<\/i> Ipilimumab versus<\/i> placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol.<\/i>, 15<\/b>, 700\u2013712 (2014)."},{"key":"11","unstructured":"11) Eggermont AM, Chiarion-Sileni V, Grob JJ, et al.<\/i> Adjuvant ipilimumab versus<\/i> placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol.<\/i>, 16<\/b>, 522\u2013530 (2015)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Robert C, Schachter J, Long GV, et al.<\/i> Pembrolizumab versus<\/i> ipilimumab in advanced melanoma. N. Engl. J. Med.<\/i>, 372<\/b>, 2521\u20132532 (2015).","DOI":"10.1056\/NEJMoa1503093"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol.<\/i>, 4<\/b>, 374\u2013378 (2018).","DOI":"10.1001\/jamaoncol.2017.2925"},{"key":"14","unstructured":"14) Michot JM, Bigenwald C, Champiat S, et al.<\/i> Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer<\/i>, 54<\/b>, 139\u2013148 (2016)."},{"key":"15","unstructured":"15) Champiat S, Lambotte O, Barreau E, et al.<\/i> Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann. Oncol.<\/i>, 27<\/b>, 559\u2013574 (2016)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Medina P, Jeffers KD, Trinh VA, Harvey RD. The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy. J. Pharm. Pract.<\/i>, 33<\/b>, 338\u2013349 (2020).","DOI":"10.1177\/0897190019885230"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Renna CE, Dow EN, Bergsbaken JJ, Leal TA. Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities. J. Oncol. Pharm. Pract.<\/i>, 25<\/b>, 954\u2013960 (2019).","DOI":"10.1177\/1078155218817937"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Ikesue H, Kusuda K, Satsuma Y, Nishiwaki F, Miura R, Masuda Y, Hirabatake M, Muroi N, Fujimoto D, Morimoto T, Tomii K, Hashida T. Evaluation of the usefulness of protocol-based pharmacist-facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer. J. Clin. Pharm. Ther.<\/i>, Epub ahead of print. 32519774 (2020).","DOI":"10.1111\/jcpt.13207"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Le S, Chang B, Pham A, Chan A. Impact of pharmacist-managed immune checkpoint inhibitor toxicities. J. Oncol. Pharm. Pract.<\/i>, Epub ahead of print. 32507100 (2020).","DOI":"10.1177\/1078155220928407"},{"key":"20","unstructured":"20) Hryniewicki AT, Wang C, Shatsky RA, Coyne CJ. Management of immune checkpoint inhibitor toxicities: a review and clinical guideline for emergency physicians. J. Emerg. Med.<\/i>, 55<\/b>, 489\u2013502 (2018)."},{"key":"21","unstructured":"21) Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, Jiang J, Robert C. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J. Clin. Oncol.<\/i>, 35<\/b>, 785\u2013792 (2017)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kimura M, Go M, Iwai M, Usami E, Teramachi H, Yoshimura T. Evaluation of the role and usefulness of a pharmacist outpatient service for patients undergoing monotherapy with oral anti-cancer agents. J. Oncol. Pharm. Pract.<\/i>, 23<\/b>, 413\u2013421 (2017).","DOI":"10.1177\/1078155216655473"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Suzuki H, Suzuki S, Kamata H, Sugama Y, Demachi K, Ikegawa K, Igarashi T, Yamaguchi M. Impact of pharmacy collaborating services in an outpatient clinic on improving adverse drug reactions in outpatient cancer chemotherapy. J. Oncol. Pharm. Pract.<\/i>, 25<\/b>, 1558\u20131563 (2019).","DOI":"10.1177\/1078155218798138"},{"key":"24","unstructured":"24) Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.<\/i>, 28<\/b> (Suppl. 4), iv119\u2013iv142 (2017)."},{"key":"25","unstructured":"25) Thompson JA, Schneider BJ, Brahmer J, et al.<\/i> NCCN guidelines insights: management of immunotherapy-related toxicities, Version 1.2020. J. Natl. Compr. Canc. Netw.<\/i>, 18<\/b>, 230\u2013241 (2020)."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Merten JA, Shapiro JF, Gulbis AM, Rao KV, Bubalo J, Lanum S, Engemann AM, Shayani S, Williams C, Leather H, Walsh-Chocolaad T. Utilization of collaborative practice agreements between physicians and pharmacists as a mechanism to increase capacity to care for hematopoietic stem cell transplant recipients. Biol. Blood Marrow Transplant.<\/i>, 19<\/b>, 509\u2013518 (2013).","DOI":"10.1016\/j.bbmt.2012.12.022"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Hansen EA, Pietkiewicz JM, Blum BL. Evaluation of the feasibility and utility of a pharmacist-centered collaborative drug therapy management program for oncology-based symptom management. J. Pharm. Pract.<\/i>, 29<\/b>, 206\u2013211 (2016).","DOI":"10.1177\/0897190014557626"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D. Overall Survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA<\/i>, 318<\/b>, 197\u2013198 (2017).","DOI":"10.1001\/jama.2017.7156"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/43\/12\/43_b20-00553\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T03:57:58Z","timestamp":1607140678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/43\/12\/43_b20-00553\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b20-00553","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}